Janux Therapeutics JANX Contract Liabilities
Contract Liabilities at other companies
Other financials
Where this comes from
Reported directly by Janux Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.
The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Janux Therapeutics's contract liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Janux Therapeutics's contract liabilities?
- Janux Therapeutics (JANX) reported contract liabilities of $8.68M in Q1 2026.
- What is the long-term trend for Janux Therapeutics's contract liabilities?
- Over 4 years (2020 to 2025), Janux Therapeutics's contract liabilities has grown at a -100.0% compound annual growth rate (CAGR), from $6.05M to $0.
- What does contract liabilities mean?
- Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.